Nanobiotix SA (FR:NANO)

:NANO

NANO

Nanobiotix

RESEARCH TOOLSreports

Want to see FR:NANO full AI Analyst Report?

Nanobiotix (NANO) Price & Analysis

Q: What was Nanobiotix SA’s price range in the past 12 months?

Nanobiotix SA lowest stock price was €3.27 and its highest was €47.66 in the past 12 months.

Q: What is Nanobiotix SA’s market cap?

Nanobiotix SA’s market cap is €2.07B.

Q: When is Nanobiotix SA’s upcoming earnings report date?

Nanobiotix SA’s upcoming earnings report date is Sep 30, 2026 which is in 132 days.

Q: Is Nanobiotix SA overvalued?

According to Wall Street analysts Nanobiotix SA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Does Nanobiotix SA pay dividends?

Nanobiotix SA does not currently pay dividends.

Q: What is Nanobiotix SA’s EPS estimate?

Nanobiotix SA’s EPS estimate is -0.12.

Q: How many shares outstanding does Nanobiotix SA have?

Nanobiotix SA has 48,401,120 shares outstanding.

Q: Which hedge fund is a major shareholder of Nanobiotix SA?

Currently, no hedge funds are holding shares in FR:NANO

Q: What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

30 Followers

NANO Stock Chart & Stats

€28.70

<€0.01(0.14%)

At close: Jan 09 4:00 PM EST

€28.70

<€0.01(0.14%)

Day’s Range― - ―

52-Week Range€3.28 - €47.66

Previous CloseN/A

Volume30.64K

Average Volume (3M)654.19K

Market Cap

€2.07B

Enterprise Value€1.83B

Total Cash (Recent Filing)€52.75M

Total Debt (Recent Filing)€95.32M

Price to Earnings (P/E)―

Beta1.07

Next Earnings

Sep 30, 2026

EPS Estimate

-0.12

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.51

Shares Outstanding48,401,120

10 Day Avg. Volume711,483

30 Day Avg. Volume654,186

Financial Highlights & Ratios

PEG Ratio0.60

Price to Book (P/B)-10.94

Price to Sales (P/S)31.19

P/FCF Ratio-27.22

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€60.00

Price Target Upside109.06% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.1

Revenue Forecast (FY)€39.31M

Bulls Say, Bears Say

Bulls Say

Clinical Efficacy And TolerabilityEarly clinical signals from the CONVERGE study suggest JNJ-1900 can enhance chemoradiation in unresectable stage III lung cancer with robust response rates and a manageable safety profile, which may reduce development risk.

Immune Response EnhancementPreclinical studies indicate that combining the Nanoprimer with mRNA and peptide vaccine approaches markedly increases both immediate and memory immune responses across vaccine types, supporting broader immuno-oncology opportunities.

Platform ExpansionAnalyst highlights that Curadigm Nanoprimer technology expands Nanobiotix beyond a single-asset radiotherapy firm into a platform that enables intravenous therapies to reach tissues outside the liver, potentially broadening future oncology and vaccine applications.

Bears Say

Commercialization And Market Uptake RiskAnalyst cautions that uncertain commercial adoption and challenges integrating a new radioenhancer into established treatment pathways could limit revenue realization even after positive clinical data.

Financial RiskAnalyst warns that funding shortfalls or constrained financial resources could delay development programs and lead to dilution, creating downside pressure on the stock.

Partnership And Intellectual Property RiskAnalyst notes that breakdowns in collaborations or intellectual property disputes could disrupt development plans and erode competitive advantages tied to the technology.

Nanobiotix News

Nanobiotix announces EUR 75M global follow-on offering

Nanobiotix (NBTX) announces the launch, subject to market and other conditions, of an approximately EUR 75M global follow-on...

9h ago

NBTX

Nanobiotix files EUR75M ordinary shares offering

16:23 EDT Nanobiotix (NBTX) files EUR75M ordinary shares offering Published first on TheFly – the ultimate source for...

11h ago

NBTX

Nanobiotix price target raised to EUR 60 from EUR 34 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Nanobiotix (NBTX) to EUR 60 from EUR 34 and keeps...

3d ago

NBTX

Nanobiotix announces FDA acceptance of NANORAY-312 study protocol amendment

Nanobiotix (NBTX) announced FDA acceptance of a protocol amendment to the ongoing pivotal NANORAY-312 study. This protocol amendment,...

16d ago

JNJ

NBTX

Nanobiotix price target raised to $30 from $3.50 at UBS

UBS raised the firm’s price target on Nanobiotix (NBTX) to $30 from $3.50 and keeps a Neutral rating...

20d ago

NBTX

Nanobiotix: Platform Expansion Potential and Risk-Adjusted NBTXR3 Valuation Support Buy Rating

Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Nanobiotix and keeping the price target at...

29d ago

NBTX

Nanobiotix price target raised to EUR 34 from EUR 32 at H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Nanobiotix (NBTX) to EUR 34 from EUR...

1M ago

NBTX

Nanobiotix Earnings Call: Deeper J&J Ties, Lower Loss

Nanobiotix SA (($FR:NANO)) has held its Q4 earnings call. Read on for the main highlights of the call....

1M ago

Nanobiotix price target raised to $36 from $26 at Guggenheim

Guggenheim raised the firm’s price target on Nanobiotix (NBTX) to $36 from $26 and keeps a Buy rating...

2M ago

NBTX

Nanobiotix: Late-Stage NBTXR3 Pipeline and Partnerships Underpin Buy-Rated Risk-Reward Profile

TD Cowen analyst Tara Bancroft has maintained their bullish stance on NBTX stock, giving a Buy rating today....

2M ago

NBTX

Nanobiotix price target raised to $37 from $26 at Leerink

Leerink analyst Jonathan Chang raised the firm’s price target on Nanobiotix (NBTX) to $37 from $26 and keeps...

2M ago

NBTX

Robust Phase 2 CONVERGE Data for JNJ-1900 Underpin Buy Rating and €32 Price Target on Nanobiotix

Analyst Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Nanobiotix and increased the price target to...

2M ago

NBTX

Nanobiotix price target raised to EUR 32 from EUR 23 at H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Nanobiotix (NBTX) to EUR 32 from EUR...

2M ago

NBTX

Nanobiotix presents first data from CONVERGE study

Nanobiotix (NBTX) announced the presentation of first data from the CONVERGE study, a Johnson & Johnson (JNJ)-sponsored randomized...

2M ago

JNJ

NBTX

NANO FAQ

What was Nanobiotix SA’s price range in the past 12 months?

Nanobiotix SA lowest stock price was €3.27 and its highest was €47.66 in the past 12 months.

What is Nanobiotix SA’s market cap?

Nanobiotix SA’s market cap is €2.07B.

When is Nanobiotix SA’s upcoming earnings report date?

Nanobiotix SA’s upcoming earnings report date is Sep 30, 2026 which is in 132 days.

How were Nanobiotix SA’s earnings last quarter?

Currently, no data Available

Is Nanobiotix SA overvalued?

According to Wall Street analysts Nanobiotix SA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Nanobiotix SA pay dividends?

Nanobiotix SA does not currently pay dividends.

What is Nanobiotix SA’s EPS estimate?

Nanobiotix SA’s EPS estimate is -0.12.

How many shares outstanding does Nanobiotix SA have?

Nanobiotix SA has 48,401,120 shares outstanding.

What happened to Nanobiotix SA’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Nanobiotix SA?

Currently, no hedge funds are holding shares in FR:NANO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Nanobiotix SA

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

Nanobiotix (NANO) Earnings & Revenues

Historic Earnings Reports

NANO Stock 12 Month Forecast

Average Price Target

€60.00

▲(109.06% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","16":"€16","31":"€31","46":"€46","61":"€61"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€60.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,16,31,46,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.72,31.126153846153844,33.53230769230769,35.93846153846154,38.34461538461538,40.75076923076923,43.15692307692308,45.56307692307692,47.96923076923077,50.37538461538462,52.78153846153846,55.18769230769231,57.59384615384616,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.72,31.126153846153844,33.53230769230769,35.93846153846154,38.34461538461538,40.75076923076923,43.15692307692308,45.56307692307692,47.96923076923077,50.37538461538462,52.78153846153846,55.18769230769231,57.59384615384616,{"y":60,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.72,31.126153846153844,33.53230769230769,35.93846153846154,38.34461538461538,40.75076923076923,43.15692307692308,45.56307692307692,47.96923076923077,50.37538461538462,52.78153846153846,55.18769230769231,57.59384615384616,{"y":60,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.975,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.7,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.1,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.88,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7.6,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.22,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.9,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.8,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.5,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.78,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.1,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.95,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.72,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >